Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | XIAP | P98170 | 13/20 | 0.43 |
| ▸ | BIRC3 | Q13489 | 8/20 | 0.42 |
| ▸ | CASP9 | P55211 | 1/20 | 0.42 |
| ▸ | BIRC2 | Q13490 | 8/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12467215 | 0.90 | XIAP (0.44) | TSHRMEN1KMT2AHTTXIAP | |
| SCHEMBL4596585 | 0.90 | TSHR (0.48) | TSHRMEN1KMT2AXIAPBIRC3 | |
| SCHEMBL4596577 | 0.86 | TSHR (0.48) | TSHRMEN1KMT2AXIAPBIRC3 | |
| SCHEMBL2163915 | 0.85 | TSHR (0.49) | TSHRXIAPBIRC3CASP9BIRC2 | |
| SCHEMBL3811996 | 0.84 | XIAP (0.46) | TSHRMEN1KMT2AHTTXIAP | |
| SCHEMBL3815275 | 0.83 | ALDH1A1 (0.51) | TSHRMEN1KMT2AHTTXIAP | |
| SCHEMBL13197251 | 0.82 | XIAP (0.52) | XIAPBIRC3CASP9BIRC2 | |
| SCHEMBL3819039 | 0.82 | MAPT (0.45) | TSHRMEN1KMT2AHTTXIAP | |
| SCHEMBL2163910 | 0.81 | TSHR (0.45) | TSHRXIAPBIRC3CASP9BIRC2 | |
| SCHEMBL2163914 | 0.81 | TSHR (0.45) | TSHRXIAPBIRC3CASP9BIRC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7932255-B2 | Controlling cell proliferation | NOVARTIS AG (CH) | 2011-04-26 | — | — | US | disclosed |
| US-20080207630-A1 | 2-Aminocarbonyl Substituted Piperazine or Diaza-Cyclic Compounds as Apoptosis Protein Inhibitors (Iap) Modulators | ECKL ROBERT | 2008-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207630-A1 | 2-Aminocarbonyl Substituted Piperazine or Diaza-Cyclic Compounds as Apoptosis Protein Inhibitors (Iap) Modulators | API5, BCL2, BIRC5 | TSHR 4087/4885MEN1 2921/4885KMT2A 3414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.